EC
ITCI

EcoR1 Capital’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

EcoR1 Capital’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q3 		– Sell
-244,950
Closed -$9.51M – 38
2016
Q2 		$9.51M Buy
+244,950
New +$8.8M 3.75% 10

Other funds holding ITCI

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
HIM
Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
WA
Wasatch Advisors Salt Lake City, Utah $15.3B AUM 25.06% 1-Year Est. Return

EcoR1 Capital's ITCI Position: Q3 2016 in Review

EcoR1 Capital sold out of Intra-Cellular Therapies Inc. (ITCI) in Q3 2016, closing a stake of 244,950 shares — an estimated $9.51M sold.

EcoR1 Capital first reported a position in ITCI in Q2 2016 and held it in 1 quarter. The position peaked at $9.51M in Q2 2016. 132 funds tracked by Wall St. Rank hold ITCI as of Q3 2016.

  • EcoR1 Capital reported no remaining Intra-Cellular Therapies Inc. position as of Q3 2016 after selling out during the quarter.
  • EcoR1 Capital sold 244,950 Intra-Cellular Therapies Inc. shares in Q3 2016, an estimated $9.51M.
  • EcoR1 Capital first reported a position in Intra-Cellular Therapies Inc. in Q2 2016 and held it in 1 quarter.
  • EcoR1 Capital's Intra-Cellular Therapies Inc. position peaked at $9.51M in Q2 2016.
  • 132 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q3 2016.

Based on EcoR1 Capital's 13F filing for Q3 2016, filed 14 Nov 2016.